PKCε inhibitor peptide, myristoylated

PKCε inhibitor peptide, myristoylated (Myr-PKCε-) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) [1].

Product Specifications

Product Name Alternative

Myr‐PKCɛ-

UNSPSC

12352209

Target

PKC

Type

Peptides

Related Pathways

Epigenetics; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pkcε-inhibitor-peptide-myristoylated.html

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](NC(CCCCCCCCCCCCC)=O)CCC(O)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(O)=O)[C@@H](C)O)=O)CCC1)=O)CCCCN)=O)CC(C)C)=O)CO)=O)C(C)C)=O)C

Molecular Formula

C51H91N9O14

Molecular Weight

1054.32

References & Citations

[1]Castro J, et al. The Effects of Novel Myristoylated PKC Epsilon Peptide Modulators on Real‐Time Nitric Oxide Release in Human Umbilical Vein Endothelial Cells. The FASEB Journal, 2020, 34 (S1) : 1-1.